Masaru Kanekiyo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/367131/publications.pdf

Version: 2024-02-01

53 papers	5,910 citations	136950 32 h-index	155660 55 g-index
65 all docs	65 docs citations	65 times ranked	7300 citing authors

#	Article	IF	Citations
1	Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature, 2013, 499, 102-106.	27.8	682
2	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature Medicine, 2015, 21, 1065-1070.	30.7	567
3	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science, 2016, 351, 1339-1342.	12.6	370
4	Prefusion Fâ€“specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Science Translational Medicine, 2015, 7, 309ra162.	12.4	312
5	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell, 2015, 162, 1090-1100.	28.9	278
6	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016, 166, 609-623.	28.9	270
7	Evaluation of candidate vaccine approaches for MERS-CoV. Nature Communications, 2015, 6, 7712.	12.8	258
8	A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nature Medicine, 2018, 24, 408-416.	30.7	235
9	Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages. Journal of Virology, 2014, 88, 4047-4057.	3.4	220
10	High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell, 2019, 179, 1636-1646.e15.	28.9	219
11	Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nature Immunology, 2019, 20, 362-372.	14.5	211
12	Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature, 2021, 592, 623-628.	27.8	180
13	Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science, 2016, 351, 1343-1346.	12.6	176
14	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. Journal of Virology, 2018, 92, .	3.4	155
15	Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. ELife, 2020, 9, .	6.0	123
16	Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. Immunity, 2019, 51, 398-410.e5.	14.3	107
17	Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. Immunity, 2019, 50, 1305-1316.e6.	14.3	107
18	Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Scientific Reports, 2016, 6, 34108.	3.3	106

#	Article	IF	Citations
19	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. MBio, 2019, 10, .	4.1	88
20	Preferential induction of cross-group influenza A hemagglutinin stemâ€"specific memory B cells after H7N9 immunization in humans. Science Immunology, 2017, 2, .	11.9	84
21	H5N1 Vaccineâ€"Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. Journal of Immunology, 2015, 195, 602-610.	0.8	83
22	Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. Immunity, 2019, 51, 735-749.e8.	14.3	71
23	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. ACS Infectious Diseases, 2018, 4, 788-796.	3.8	65
24	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine, 2022, 28, 383-391.	30.7	65
25	Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. JCI Insight, 2020, 5, .	5.0	64
26	Priming-Boosting Vaccination with Recombinant Mycobacterium bovis Bacillus Calmette-Gueìrin and a Nonreplicating Vaccinia Virus Recombinant Leads to Long-Lasting and Effective Immunity. Journal of Virology, 2005, 79, 12871-12879.	3.4	60
27	Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nature Communications, 2017, 8, 14158.	12.8	58
28	Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nature Communications, 2017, 8, 1877.	12.8	53
29	New Vaccine Design and Delivery Technologies. Journal of Infectious Diseases, 2019, 219, S88-S96.	4.0	53
30	In vitro reconstitution of B cell receptorâ€"antigen interactions to evaluate potential vaccine candidates. Nature Protocols, 2016, 11, 193-213.	12.0	51
31	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	49
32	A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. Nature Communications, 2021, 12, 1722.	12.8	41
33	Mycobacterial Codon Optimization Enhances Antigen Expression and Virus-Specific Immune Responses in Recombinant Mycobacterium bovis Bacille Calmette-Gueìrin Expressing Human Immunodeficiency Virus Type 1 Gag. Journal of Virology, 2005, 79, 8716-8723.	3.4	37
34	Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. Nature Communications, 2020, 11, 791.	12.8	36
35	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. Journal of Virology, 2013, 87, 2294-2306.	3.4	34
36	Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation. Scientific Reports, 2016, 6, 36298.	3.3	29

#	Article	IF	Citations
37	Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity. Journal of Immunology, 2009, 183, 2425-2434.	0.8	27
38	Epitope-Specific Serological Assays for RSV: Conformation Matters. Vaccines, 2019, 7, 23.	4.4	26
39	Enhanced Induction of Intestinal Cellular Immunity by Oral Priming with Enteric Adenovirus 41 Vectors. Journal of Virology, 2009, 83, 748-756.	3.4	25
40	Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity. Journal of Virology, 2009, 83, 7166-7175.	3.4	23
41	Next-Generation Influenza Vaccines. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038448.	6.2	23
42	Structure-based design of stabilized recombinant influenza neuraminidase tetramers. Nature Communications, 2022, 13, 1825.	12.8	21
43	Comparison of adjuvants to optimize influenza neutralizing antibody responses. Vaccine, 2019, 37, 6208-6220.	3.8	16
44	A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Nature Medicine, 2022, 28, 373-382.	30.7	16
45	A novel CD4â€conjugated ultraviolet lightâ€activated photocatalyst inactivates HIVâ€1 and SIV efficiently. Journal of Medical Virology, 2008, 80, 1322-1331.	5.0	14
46	An R848-Conjugated Influenza Virus Vaccine Elicits Robust Immunoglobulin G to Hemagglutinin Stem in a Newborn Nonhuman Primate Model. Journal of Infectious Diseases, 2020, 224, 351-359.	4.0	14
47	Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem. JCI Insight, 2020, 5, .	5.0	13
48	A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcÎ³R-mediated protection against heterologous lethal influenza virus infection. International Immunology, 2019, 31, 81-90.	4.0	12
49	Intradermal Delivery of Recombinant Vaccinia Virus Vector DIs Induces Gutâ€Mucosal Immunity. Scandinavian Journal of Immunology, 2010, 72, 98-105.	2.7	7
50	High-Throughput B Cell Epitope Determination by Next-Generation Sequencing. Frontiers in Immunology, 2022, 13, 855772.	4.8	7
51	Mucosal Administration of Completely Nonâ€Replicative Vaccinia Virus Recombinant Dairen I strain Elicits Effective Mucosal and Systemic Immunity. Scandinavian Journal of Immunology, 2008, 68, 476-483.	2.7	3
52	Virus-Like Particle and Nanoparticle Vaccines. , 2017, , 87-98.		3
53	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. Frontiers in Immunology, 2021, 12, 662909.	4.8	0